Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APT3711
- Development stage
- Preclinical
- Lead developer
- Ampeptec
- Modality
- Peptides
- Administration
- Oral, Subcutaneous
01
Overview
APT3711 is a fully synthetic peptide analog of glucagon-like peptide-1 (GLP-1) (7-36) incorporating unnatural amino acids to improve chemical and proteolytic stability. Developed by Ampeptec, the drug acts as a long-acting GLP-1 receptor agonist. Preclinical studies in rats and minipigs have demonstrated a significantly prolonged half-life compared to semaglutide and tirzepatide, suggesting potential for once-monthly subcutaneous injection or once-weekly oral administration. APT3711 is being developed for the treatment of obesity and type 2 diabetes.
02
Targets
Beyond the preview
Go deeper on APT3711.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APT3711.